APA (7th ed.) Citation

DY, Y., S, R., A, G., PC, M., A, R., C, S., . . . S, S. (2026). IGLV3-21R110 and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL. HemaSphere, 10(6), e70385. https://doi.org/10.1002/hem3.70385

Chicago Style (17th ed.) Citation

DY, Yosifov, et al. "IGLV3-21R110 and Ibrutinib Treatment: Results from the Double-blind, Randomized, Placebo-controlled GCLLSG CLL12 Trial in Early-stage CLL." HemaSphere 10, no. 6 (2026): e70385. https://doi.org/10.1002/hem3.70385.

MLA (9th ed.) Citation

DY, Yosifov, et al. "IGLV3-21R110 and Ibrutinib Treatment: Results from the Double-blind, Randomized, Placebo-controlled GCLLSG CLL12 Trial in Early-stage CLL." HemaSphere, vol. 10, no. 6, 2026, p. e70385, https://doi.org/10.1002/hem3.70385.